Theralase Granted US Patent for Multiwavelength Photodynamic Therapy

Theralase Technologies Inc. recently announced it has been granted a US Patent for Multiwavelength PhotoDynamic Therapy (PDT) technology.

The US patent, titled Apparatus and Method for Multiwavelength Photodynamic Therapy, allows Theralase to use various laser wavelengths in the activation of PhotoDynamic Compounds (PDC) in cancerous tumors. The advantage is that a large or deep seated tumor may be only partially destroyed with laser of a particular wavelength, but then fully destroyed by employing one or two additional laser wavelengths, as different laser wavelengths are able to penetrate to different tissue depths. This would be especially important for cancers, such as Glio Blastoma Multiforme (GBM) or Non-Small Cell Lung Cancer (NSCLC).

Dr. Arkady Mandel, MD, PhD, DSc, Chief Scientific Officer of Theralase, said “Theralase specializes in the development of safe, effective, and targeted cancer therapy. This US patent increases company value by protecting optimized PDT technology, which would be effective in large or difficult-to-reach tumors that are not accessible by certain laser wavelengths. Theralase continues to develop a comprehensive intellectual property portfolio, which strengthens Theralase’s position in the global oncology market.”

The global market for oncology therapeutic medicines will reach as high as $200 billion by 2022, with the US market reaching as high as $100 billion by 2022, averaging 12% to 15% growth.

Theralase is a clinical-stage pharmaceutical company dedicated to the research and development of light-activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers. For more information, visit and